Development of sulfasalazine-associated drug-induced lupus erythematosus in patient with rheumatoid arthritis (clinical case)
https://doi.org/10.33667/2078-5631-2021-16-26-29
Abstract
Drug-induced lupus syndrome (DLS) is a rare adverse event with a variety of drugs. More than a hundred of drugs are known that can cause the development of DLS, and this list is growing as new drugs appear. Physicians of any specialty can face such complications of therapy and should be aware of this pathology. The article presents an analysis of a clinical case of DLS development against the background of long-term administration of sulfasalazine in a patient with a reliable diagnosis of rheumatoid arthritis, as well as a literature review, which includes data on the prevalence, drug groups, clinical manifestations, diagnosis and treatment of this pathology.
About the Authors
A. N. Kovshik
A. S. Loginov Moscow Clinical Scientific Center
Russian Federation
Russian Federation
Kovshik Anton N., rheumatologist at Dept of Rheumatology
E. P. Kiseleva
A. S. Loginov Moscow Clinical Scientific Center
Russian Federation
Russian Federation
Kiseleva Ekaterina P., rheumatologist at Dept of Rheumatology
N. G. Klyukvina
A. S. Loginov Moscow Clinical Scientific Center
Russian Federation
Russian Federation
Klyukvina Natalia G., DM Sci, leading researcher at Research Dept
of Rheumatology
G. V. Lukina
A. S. Loginov Moscow Clinical Scientific Center; V. A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Lukina Galina V., DM Sci, professor, head of Research Division of Rheumatology; lead researcher at Dept of Comorbid Infections and Monitoring the Safety of Drug Therapy
References
1. Klyukvina NG, Gunchikova VM, Novikova AM. Drug-induced lupus. Sovremennaya Revmatologiya = Modern Rheumatology. 2018; 12 (4): 32–41. https://doi. org/10.14412/1996–7012–2018–4–32–41
2. Augusto Vaglio, Peter C. Grayson, Paride Fenaroli, Davide Gianfreda, Valeria Boccaletti, Gian Marco Ghiggeri, Gabriella Moroni, Drug-induced lupus: Traditional and new concepts. Autrev (2018), DOI: 10.1016/j.autrev.2018.03.016.
3. Solhjoo M, Bansal P, Goyal A, Chauhan K. Drug-Induced Lupus Erythematosus. 2021 Jan 27. In: StatPearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2021 Jan. PMID: 28722919.
4. Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann NY Acad Sci. 2007 Jun; 1108: 166–82. DOI: 10.1196/annals.1422.019. PMID: 17893983.
5. Harnett DT, Chandra-Sekhar HB, Hamilton SF. Drug-induced lupus erythematosus presenting with cardiac tamponade: a case report and literature review. Can J Cardiol. 2014 Feb; 30 (2): 247. e11–2. DOI: 10.1016/j.cjca.2013.11.011. Epub 2013 Nov 16. PMID: 24373757.
6. Kirkpatrick AW, Bookman AA, Habal F. Lupus-like syndrome caused by 5-aminosalicylic acid in patients with inflammatory bowel disease. Can J Gastroenterol. 1999 Mar; 13 (2): 159–62. DOI: 10.1155/1999/361431. PMID: 10203437.
7. Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009 Jan; 301 (1): 99–105. DOI: 10.1007/s00403–008– 0895–5. Epub 2008 Sep 17. PMID: 18797892.
8. Pérez-De-Lis M, Retamozo S, Flores-Chávez A, Kostov B, Perez-Alvarez R, BritoZerón P, Ramos-Casals M. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opin Drug Saf. 2017 Nov; 16 (11): 1255–1271. DOI: 10.1080/14740338.2017.1372421. Epub 2017 Sep 7. PMID: 28854831.
9. He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol. 2018; 30 (5): 490–497. DOI: 10.1097/ BOR.0000000000000522.
Review
For citations:
Kovshik A.N., Kiseleva E.P., Klyukvina N.G., Lukina G.V. Development of sulfasalazine-associated drug-induced lupus erythematosus in patient with rheumatoid arthritis (clinical case). Medical alphabet. 2021;(16):26-29. (In Russ.) https://doi.org/10.33667/2078-5631-2021-16-26-29
Views:
780
Email this article 